U.S. Sen. John Kennedy's (R-La.) failed amendment to the Inflation Reduction Act would have required health centers to make insulin and EpiPens available at or below 340B price and would have helped cover centers' direct costs of doing so. A leading health center advocate panned the amendment.
Senate Rejects 340B-Related Amendment to Major Drug Pricing and Climate Change Bill
The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
